Study summary
Guselkumab nearly tripled remission rates compared with placebo
23%in remission at 12 weeks, vs 8% with placebo
What was tested
Guselkumab, an antibody that blocks IL-23, against placebo, for moderately to severely active ulcerative colitis not controlled by other treatments.
What they found
- Clinical remission at 12 weeks was 23% vs 8%.
- Side effect rates were similar to placebo.
What it means
Added guselkumab to the IL-23 drug class already used for Crohn's disease and psoriasis.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.